Symposium

Treating All of MS: Unifying Strategies to Target Relapse and Progression in a Shifting Clinical Landscape

Launch Date
10/22/2026 at 01:15 pm EDT
Credit Amount
1
Credit Expires
10/22/2026

Faculty

Stephen Krieger, MD, FAAN
Moderator
Professor of Neurology
Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, NY
Cristina Granziera, MD, PhD
Chief Physician and Head of Neurology Department, Basel University Hospital
Head of Translational Imaging in Neurology
ThINk Basel, University of Basel
Co-Director of Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)
Basel, Switzerland
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

It is increasingly understood that multiple sclerosis (MS) relapse and progression can occur simultaneously, regardless of phenotype, revealing flaws in the traditional classification of MS and prompting increasing use of a spectrum-based view of the disease. This shift is reflected in updated diagnostic criteria and an ongoing shift to a spectrum-based view of MS, leading health care professionals (HCPs) to reconsider how MS is defined, monitored, and treated. In particular, this raises a key question as to whether relapse and progression should always be targeted simultaneously and what that means in a traditionally relapse-driven treatment armamentarium. With few available options to treat both relapse and progression, there is increasing interest in personalizing B-cell–targeting therapies to best meet the needs of patients. Further, with Bruton’s tyrosine kinase inhibitors (BTKis) beginning to see their first regulatory approvals around the world, it is important to understand how clinicians may leverage these tools within this spectrum-based approach to care.

In this EfficientCME live symposium, expert faculty will discuss the ongoing shift to a spectrum-based approach to MS and its implications; the individualization of currently available tools to address the concurrent management of relapse and progression; and the anticipated role and sequencing of emerging BTKis in the management of MS.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Analyze the role and impact of progression in relapsing disease and use this concept to frame clinical decision-making
  • Incorporate currently available tools to enhance and individualize the simultaneous treatment of both relapse and progression
  • Determine the role and sequencing of emerging BTKis to refine the spectrum approach to MS

Financial Support

Supported by an educational grant from Genentech, a member of the Roche Group.

Target Audience

MS specialists/neuroimmunologists, general neurologists, nurse practitioners (NPs), and physician associates (PAs) working in neurology settings

Credit Information

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC, and EfficientCME. CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.00 Contact Hours.

Physician Associates (AAPA): 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Krieger reports the following financial relationships:

Consultant/Advisory Work: Biogen; Cycle Pharmaceuticals; EMD Serono; Genentech, Inc; MedRX; Novartis; PTC Therapeutics; TG Therapeutics, Inc.; and Zenas BioPharma, Inc.

Research Support: Biogen; Bristol-Myers Squibb; Novartis; and Sanofi-Genzyme

Speakers Bureau: Non-promotional speaking with Genentech, Inc and TG Therapeutics, Inc.

Dr. Granziera has no financial relationships to disclose

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Lexie Oneca (Planning Committee)
Chloe Billings, MS (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MM-164-102226-31

Treating All of MS: Unifying Strategies to Target Relapse and Progression in a Shifting Clinical Landscape
Event Date: 10/22/2026 at 01:15 pm EDT
Register